CompletedNot Applicable

Active Clearance Technology (ACT) Registry

United States500 participantsStarted 2016-05-10

Plain-language summary

The purpose of this study is to evaluate the effectiveness of the PleuraFlow® Active Clearance Technology™ (ACT) System in the management of blood evacuation after cardiac surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or Female subjects 18 years of age or older who received a PleuraFlow System following heart surgery.
✓. Patient undergoing cardiac surgery via sternotomy

Exclusion criteria

✕. Robotic surgery
✕. Any access via thoracotomy
✕. Any condition deemed inappropriate for inclusion by the investigators.
✕. Intolerance to implantable silicone materials.

What they're measuring

Number of interventions to Treat Retained Blood Syndrome

Timeframe: Discharge from operating room for index-surgery through hospital discharge - approximate 30 days

Trial details

NCT IDNCT02682849

SponsorJohn M. Stulak

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-05

View on ClinicalTrials.gov More Retained Blood Syndrome trials